Brief: Allakos Announces Phase 2 Lirentelimab Trials In Atopic Dermatitis And Chronic Spontaneous Urticaria Did Not Meet Their Primary Endpoints
16/01/2024 12:12
Jan 16 (Reuters) - Allakos Inc ALLK.O :
* ALLAKOS ANNOUNCES PHASE 2 LIRENTELIMAB TRIALS IN ATOPIC
DERMATITIS AND CHRONIC SPONTANEOUS URTICARIA DID NOT MEET THEIR
PRIMARY ENDPOINTS
* ALLAKOS INC - ALLAKOS PLANS NOT TO PURSUE FURTHER
DEVELOPMENT OF
LIRENTELIMAB
* ALLAKOS INC - WILL FOCUS ON AK006 CLINICAL DEVELOPMENT AND
ADDITIONAL PRECLINICAL PROGRAMS
* ALLAKOS INC - TRIALS DID NOT MEET THEIR PRIMARY ENDPOINT
Source text for Eikon: ID:nGNX34stBl
Further company coverage: ALLK.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Allakos
See all newsAllakos Inc reports results for the quarter ended March 31 - Earnings Summary
Allakos Inc expected to post a loss of 29 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-M-tron, Rocket Companies, TKO Group
Allakos soars on buyout deal with Concentra Biosciences
Brief: Allakos Inc. Enters Into Agreement To Be Acquired By Concentra Biosciences